In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...

Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

US stocks closed in the red on Wednesday after the Federal Reserve said it would bide its time before making any further ...

The chip maker is scheduled to report earnings and its full-year performance after the market close Thursday. Intel will report its Q4 earnings after the bell Thursday.